Antibody drug conjugates — a class of targeted medications that combine monoclonal antibodies with cytotoxic payloads — are rapidly changing the treatment landscape for patients with metastatic breast cancer .
"Prophylactic cryotherapy — ice chips or ice water held in the mouth throughout the infusion — was also suggested," she said. "There was one patient who had a grade 5 event, which was characterized by the investigator as grade 3 pneumonitis, with death attributed to disease progression," Jhaveri said. This was subsequently adjudicated to be a grade 5 drug-related death.
Any grade diarrhea was reported in 7.5%, with no grade 3+ diarrhea. Alopecia was reported in 36.4%, of which grade 1 was 21% and grade 2 was 15%. Median overall survival was 35.7 months with trastuzumab deruxtecan vs 25.0 months with the treatment of choice, with the risk for death reduced by 31% with trastuzumab deruxtecan .
Source: Healthcare Press (healthcarepress.net)
Metastatic Breast Carcinoma Metastatic Breast Cancer MBC Mbc Advanced BC Metastatic BC Metastatic Breast Cancer (MBC) MBC - Metastatic Breast Cancer Biologic Therapy Biologics Breast Cancer Malignant Breast Neoplasm Breast Carcinoma Antineoplastic Drug Anti-Cancer Agents Erlotinib Gefitinib Imatinib Rituximab Su11248 Sunitinib Trastuzumab Dentistry
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: mercnews - 🏆 88. / 68 Read more »
Source: FOX10Phoenix - 🏆 83. / 68 Read more »
Source: axios - 🏆 302. / 63 Read more »
Source: ForbesTech - 🏆 318. / 59 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: ScienceDaily - 🏆 452. / 53 Read more »